Hepatocellular Carcinoma (HCC) and Transarterial ChemoEmbolization (TACE)

Hepatocellular carcinoma (HCC) is the most widely recognized kind of essential liver growth in grown-ups and is the most well-known reason for death in individuals with cirrhosis. It happens in the setting of incessant liver aggravation and is most firmly connected to endless viral hepatitis contamination (hepatitis B or C) or introduction to poisons, for example, liquor or Aflatoxin. Certain ailments, for example, hemochromatosis and alpha 1-antitrypsin lack, particularly increment the danger of treating HCC. Similarly, as with any malignancy, the treatment and forecast of HCC differ contingent upon the specifics of tumor histology, measure, how far growth has spread, and in general wellbeing. 

  • HCC Management
  • Immune Therapy
  • Molecular Targeted Agents
  • Advanced Stages
  • Sorafenib

Related Conference of Hepatocellular Carcinoma (HCC) and Transarterial ChemoEmbolization (TACE)

October 29-30, 2018

4th World Congress on Digestive & Metabolic Diseases

| San Francisco, California, USA
November 07-08, 2018

World Summit on Liver Cirrhosis and Hepatitis

Singapore
December 17-18, 2018

3rd World Liver Congress

Abu Dhabi, UAE
January 30-31, 2019

16th World Congress on Gastroenterology & Therapeutics

Bangkok, Thailand
March 04-05, 2019

20th World Congress on Gastroenterology

Berlin, Germany
June 17-18, 2019

World Liver Conference 2019

Columbus, Ohio, U.S.A
July 08-09, 2019

14th Euro-Global Gastroenterology Conference

Zurich, Switzerland
July 15-16, 2019

7th International Conference on Hepatology

Sydney, Australia
October 14-15, 2019

19th World Gastroenterologists Summit

Sydney, Australia

Hepatocellular Carcinoma (HCC) and Transarterial ChemoEmbolization (TACE) Conference Speakers

Recommended Sessions

Related Journals

Are you interested in